The Company owns exclusive rights to multiple patent families covering a number of products, disease targets, and associated natural human antibody production and purification technologies.

Patrys also owns the technologies associated with human B cell immortalization (key to antibody capture).

The competitive advantages associated with Patrys’ comprehensive patent strategy means that Patrys can potentially block others from developing antibodies that are similar to our lead products and potentially from developing any products that bind to the same cancer disease targets.

We have filed patent applications in key jurisdictions and have been granted patents in the US, Europe, Canada and Australia among other countries.